Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 234Squamous Cell Carcinoma of Head and Neck 168Head and Neck Neoplasms 141Lung Neoplasms 110Esophageal Neoplasms 109Nasopharyngeal Carcinoma 104Uterine Cervical Neoplasms 101Stomach Neoplasms 88Esophageal Squamous Cell Carcinoma 86Breast Neoplasms 69Urinary Bladder Neoplasms 66Small Cell Lung Carcinoma 58Pancreatic Neoplasms 56Neoplasms 55Carcinoma, Squamous Cell 55Cholangiocarcinoma 52Ovarian Neoplasms 45Neoplasm Metastasis 44Oropharyngeal Neoplasms 43Biliary Tract Neoplasms 41Adenocarcinoma Of Esophagus 35Recurrence 29Mesothelioma, Malignant 28Triple Negative Breast Neoplasms 25Laryngeal Neoplasms 25Nasopharyngeal Neoplasms 24Lymphoma 24Gallbladder Neoplasms 24Sarcoma 21Carcinoma 21

Interventions

Nivolumab 3Cisplatin 2Albumin-Bound Paclitaxel 2tislelizumab 1spartalizumab 1Taxes 1Standard of Care 1Radiotherapy 1Neoadjuvant Therapy 1Immunotherapy 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Muscle-Invasive Bladder Carcinoma × Cisplatin × Clear all
NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting
32 enrolled

Muscle-Invasive Bladder Carcinoma

NCT04909775 2021-06-02

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Ruijin Hospital

Phase 2 Unknown
40 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡